UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 441

Sortiert nach

Long road towards effective HER3 targeting in breast cancer

Cancer treatment reviews, 2024-09, Vol.129, p.102786, Article 102786

2024

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

Molecular carcinogenesis, 2024-08, Vol.63 (8), p.1528-1541

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Journal of translational medicine, 2024-07, Vol.22 (1), p.665-15, Article 665

2024

Link zum Volltext

Verfügbarkeit prüfen

Self-inhibition of HER2 and HER3 at fever temperatures may prevent their hetero-dimerization

Journal of biomolecular structure & dynamics, 2024-07, Vol.42 (10), p.5470-5473

2024

Link zum Volltext

Verfügbarkeit prüfen

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance

Breast cancer research : BCR, 2024-06, Vol.26 (1), p.1-16, Article 107

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Genes & diseases, 2024-06, p.101354, Article 101354

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?

World journal of surgical oncology, 2024-05, Vol.22 (1), p.131-131, Article 131

2024

Link zum Volltext

Verfügbarkeit prüfen

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

Journal of translational medicine, 2024-04, Vol.22 (1), p.362-362, Article 362

2024

Link zum Volltext

Verfügbarkeit prüfen

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

Cancer, 2024-04, Vol.130 (S8), p.1392-1402

2024

Link zum Volltext

Verfügbarkeit prüfen

SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs

Acta pharmacologica Sinica, 2024-04, Vol.45 (4), p.857-866

2024

Link zum Volltext

Verfügbarkeit prüfen

Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

Breast cancer research and treatment, 2024-04, Vol.204 (3), p.631-642

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Cancer reports, 2024-03, Vol.7 (3), p.e1954-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors

Translational lung cancer research, 2024-02, Vol.13 (2), p.321-333

2024

Link zum Volltext

Verfügbarkeit prüfen

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Future oncology (London, England), 2024-02, Vol.20 (16), p.1057-1067

2024

Link zum Volltext

Verfügbarkeit prüfen

Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

Investigational new drugs, 2024-02, Vol.42 (1), p.14-23

2024

Link zum Volltext

Verfügbarkeit prüfen

Targeting HER3 to overcome EGFR TKI resistance in NSCLC

Frontiers in immunology, 2024-01, Vol.14, p.1332057-1332057

2024

Link zum Volltext

Verfügbarkeit prüfen

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

Future oncology (London, England), 2024-01

2024

Link zum Volltext

Verfügbarkeit prüfen

A familial case of extramammary Paget disease: Analysis of whole-exome sequencing

EJC skin cancer, 2024, Vol.2, p.100025, Article 100025

2024

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Frontiers in immunology, 2024, Vol.15, p.1376045-1376045

2024

Link zum Volltext

Verfügbarkeit prüfen

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

Cancer biology & therapy, 2023-12, Vol.24 (1), p.2256906-2256906

2023

Link zum Volltext

Verfügbarkeit prüfen

ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

Cancers, 2023-12, Vol.15 (24), p.5886

2023

Link zum Volltext

Verfügbarkeit prüfen

Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study

Cancers, 2023-11, Vol.15 (22), p.5446

2023

Link zum Volltext

Verfügbarkeit prüfen

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

Cancer cell international, 2023-09, Vol.23 (1), p.1-204, Article 204

2023

Link zum Volltext

Verfügbarkeit prüfen

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

International journal of biological macromolecules, 2023-09, Vol.248, p.125867-125867, Article 125867

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 441

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(369)
Mit Volltextzugriff
(419)

Publikationsform

Artikel
(422)
Buchkapitel
(10)
Berichte
(7)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Long road towards effective HER3 targeting in breast cancer

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

HER3 receptor and its role in the therapeutic management of metastatic breast cancer

Self-inhibition of HER2 and HER3 at fever temperatures may prevent their hetero-dimerization

A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

HER3 (ERBB3) amplification in liposarcoma - a putative new therapeutic target?

DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors

Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer

SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs

Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide

Targeting HER3 to overcome EGFR TKI resistance in NSCLC

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

A familial case of extramammary Paget disease: Analysis of whole-exome sequencing

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

Suchergebnisse filtern